• Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

Alzheimer's Drug Delay, 12/17/12


Eli Lilly announced it needed to work a few more years on its Alzheimer's drug, causing its stock to drop. Meanwhile, Johnson & Johnson got a needed nod of approval for its underappreciated pharmaceutical division.

Although Christmas isn’t until next week, Wall Street traders will be gearing up for the holiday with less and less of them around. This means that as the week progresses there will be overreaction to any news on light trading sessions. Just remember those sharp moves up or down are unlikely to last.


Although even Warren Buffett doesn’t want to deal with holding Johnson & Johnson’s stock, said that J&J is on the mend. Eli Lilly won’t be sending its Alzheimer’s drug to the FDA any time soon because it needs to work on it a few more years.

Federal Express is reporting this week, which is important since they are a true harbinger of the economy. The company also has a long history of being accurate and forthcoming even if things aren’t going well.

FDA is looking at Hemispherx BioPharma’s chronic fatigue syndrome drug, which is particularly interesting since there is little agreement on the disease; let alone how to treat it, Marek says.

If you have any questions for Marek, he can be contacted through Twitter at @MarekFuchs.

Watch past Wall Street Wrap Up videos here.

Marek Fuchs was a stockbroker for Shearson Lehman Brothers before becoming a journalist who wrote The New York Times' "County Lines" column for six years. Marek speaks regularly on business and journalism issues at venues ranging from annual meetings of the Society of American Business Editors and Writers to PBS to National Public Radio. His last book, A Cold-Blooded Business, was called "riveting" by Kirkus Reviews and next book, Local Heroes: Portraits of American Volunteer Firefighters is due out in 2012. He is on the writing faculty at Sarah Lawrence College. When Marek is not writing, teaching or filming videos, he serves as a volunteer firefighter.

Related Videos
Victor J. Dzau, MD, gives expert advice
Victor J. Dzau, MD, gives expert advice